NDAORALSOLUTION
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
BRYNOVIN (sitagliptin hydrochloride oral) by R-Pharm US is dipeptidyl peptidase 4 inhibitors [moa]. Approved for type 2 diabetes mellitus. First approved in 2025.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRYNOVIN is a dipeptidyl peptidase-4 (DPP-4) inhibitor oral solution containing sitagliptin hydrochloride, approved January 16, 2025. It is indicated for type 2 diabetes mellitus management and works by inhibiting DPP-4 to increase incretin levels, enhancing glucose-dependent insulin secretion. The oral solution formulation differentiates it from existing tablet-based DPP-4 competitors in the market.
Growth14.5 years to LOE
Early growth-stage product with newly approved formulation presents opportunity for commercial team expansion in market penetration and payer negotiations.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications (1)
Career Relevance
BRYNOVIN is a newly launched growth-stage product with formulation differentiation in a mature diabetes market, creating near-term demand for commercial and market access talent. Job opportunities will concentrate on payer education, formulary positioning, and field-based promotion against entrenched generic and branded competitors.
Worked on BRYNOVIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.